IDH1 and central nervous system cancer: Preclincial studies have shown that the DNA methylation inhibitor 5-aza-2′-deoxycytidine (5-azadC) effectively reverses DNA hypermethylation observed in IDH1 mutant gliomas, induces tumor stem cell differentiation, and inhibits tumor growth in mouse models [46].